Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval ofREZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive…